Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

NCT06745908 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT06745908
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06745908 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2025
Completion date
January 31, 2029
Enrollment
507 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv